Merck, Inc.
Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)
- Conditions
- Hospital-Acquired Bacterial PneumoniaVentilator-Associated Bacterial Pneumonia
- Interventions
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 274
- Registration Number
- NCT03583333
- Locations
- 🇨🇳
Peking University First Hospital ( Site 0131), Beijing, Beijing, China
🇨🇳Zhongshan Hospital Affiliated to Xiamen University ( Site 0133), Xiamen, Fujian, China
🇨🇳The Seventh Medical Center of PLA General Hospital-Intensive medicine ( Site 0157), Beijing, Beijing, China
Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT03569033
- Locations
- 🇬🇧
Hvivo Service Limited. Queen Mary BioEnterprises ( Site 0003), London, United Kingdom
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: Prevnar 13™Biological: V114Biological: PNEUMOVAX™23
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 277
- Registration Number
- NCT03565900
- Locations
- 🇦🇺
St. Vincent's Hospital ( Site 0041), Sydney, New South Wales, Australia
🇧🇷Hospital Sao Rafael ( Site 0049), Salvador, Bahia, Brazil
🇺🇸Baylor College of Medicine - Texas Children's Hospital ( Site 0165), Houston, Texas, United States
A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 75
- Registration Number
- NCT03565068
- Locations
- 🇺🇸
California Clinical Trials ( Site 0001), Glendale, California, United States
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 442
- Registration Number
- NCT03564691
- Locations
- 🇨🇦
Princess Margaret Cancer Centre ( Site 0033), Toronto, Ontario, Canada
🇺🇸Seattle Cancer Care Alliance ( Site 0010), Seattle, Washington, United States
🇺🇸University of California at San Francisco ( Site 0004), San Francisco, California, United States
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 976
- Registration Number
- NCT03553836
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute ( Site 0029), Los Angeles, California, United States
🇺🇸Winship Cancer Institute of Emory University ( Site 0046), Atlanta, Georgia, United States
🇺🇸UCLA Hematology & Oncology ( Site 0130), Los Angeles, California, United States
MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5
- Registration Number
- NCT03552536
- Locations
- 🇩🇪
Charite Research Organisation GmbH ( Site 0001), Berlin, Germany
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
- Conditions
- Melanoma
- Interventions
- Biological: INTRON ABiological: PEG-Intron
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 126
- Registration Number
- NCT03552549
Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 29
- Registration Number
- NCT03554005
Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- Biological: Interferon alfa-2bBiological: Pegylated interferon alfa-2b
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 344
- Registration Number
- NCT03547154